This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Azelon Pharmaceuticals.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Azelon Pharmaceuticals Identifier:
First received: May 18, 2012
Last updated: May 21, 2012
Last verified: May 2012
This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.

Condition Intervention Phase
Osteoporosis Osteopenia Drug: ZT-034 Low Dose Nasal Spray Drug: ZT-034 Mid Dose Nasal Spray Drug: ZT-034 High Dose Nasal Spray Drug: Teriparatide Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass

Resource links provided by NLM:

Further study details as provided by Azelon Pharmaceuticals:

Primary Outcome Measures:
  • Change in Serum P1NP from baseline to end of treatment. [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Change in serum calcium and incidence of hypercalcemia (pre-dose and post-dose) [ Time Frame: baseline and 6 weeks ]

Enrollment: 130
Study Start Date: November 2011
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low Dose Nasal Spray Drug: ZT-034 Low Dose Nasal Spray
Nasal Spray
Experimental: Mid Dose Nasal Spray Drug: ZT-034 Mid Dose Nasal Spray
Nasal Spray
Experimental: High Dose Nasal Spray Drug: ZT-034 High Dose Nasal Spray
Nasal Spray
Active Comparator: Forteo
20ug subcutaneous injection daily
Drug: Teriparatide
20 mcg subcutaneous daily
Other Name: Forteo
Placebo Comparator: Placebo Nasal Spray Drug: Placebo
Nasal Spray


Ages Eligible for Study:   45 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal Females Age ≥ 45 years.
  • Weight > 45 kg and < 90 kg
  • Normal nasal examination at baseline.
  • Low bone mass at lumbar spine, total hip or femoral neck (BMD T-score of ≤ - 1.5 or lower) or a recent (within 5 years of baseline) history of fragility fracture (excluding fractures of hands, feet, face and/or skull) and a T-score of -1.0 or lower at lumbar spine, total hip or femoral neck

Exclusion Criteria:

  • Serious Medical Condition
  • History of diseases which affect bone metabolism other than postmenopausal osteoporosis such as Paget's disease, any secondary causes of osteoporosis, hypoparathyroidism, or hyperparathyroidism
  • Have a history of cancer within the past 5 years, except for basal cell carcinoma
  • Have hypocalcemia or hypercalcemia from any cause or have a recent history of kidney stones or pre-existing hypercalciuria;
  • Have used any of the mostly commonly prescribed osteoporosis medications within 3 months of starting the investigational product, or for more than 1 month at any time within 6 months prior to starting investigational product
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01604057

Sponsors and Collaborators
Azelon Pharmaceuticals
Study Director: Brian MacDonald Azelon Pharmaceuticals
  More Information

Responsible Party: Azelon Pharmaceuticals Identifier: NCT01604057     History of Changes
Other Study ID Numbers: ZT-3201
Study First Received: May 18, 2012
Last Updated: May 21, 2012

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 20, 2017